Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the pharyngitis treatment market right now?

The pharyngitis treatment market has expanded steadily, increasing from $2.27 billion in 2024 to $2.37 billion in 2025, with a CAGR of 4.5%. Growth has been driven by the high prevalence of flu, rising pharyngitis cases, increased awareness, better access to healthcare, and higher disposable incomes.

How fast Is the pharyngitis treatment market expected to grow, and what’s its future value?

The pharyngitis treatment market is anticipated to expand, reaching $2.99 billion in 2029 with a CAGR of 6.0%. Growth factors include the increasing adoption of rapid point-of-care tests, demand for personalized medicine, antibiotic resistance concerns, and a heightened focus on hand hygiene. Emerging trends include advancements in pharyngitis therapy research, digital health integration, and telehealth expansion.

Get your pharyngitis treatment market report here!

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

What are the leading drivers of growth in the pharyngitis treatment market?

A surge in strep throat cases is poised to drive the growth of the pharyngitis treatment market. Strep throat is an infectious bacterial ailment predominantly affecting the throat and tonsils. Swift and effective treatment of strep throat using antibiotics can reduce symptoms, stave off complications, and lower the risk of transferring the infection to others. Data from the Centers for Disease Control and Prevention in June 2022 indicated that an estimated 14,000 to 25,000 invasive group A strep disease cases occur in the United States annually. Strep illnesses also account for approximately 5.2 million outpatient visits and 2.8 million annual antibiotic prescriptions. Consequently, strep throat’s escalating transmission bolsters the pharyngitis treatment market. The pharyngitis treatment market is also expected to be driven by an increase in influenza cases. Influenza, or the flu, is an infectious respiratory disease caused by influenza viruses. Pharyngitis treatment, typically used to manage influenza, mitigates the symptoms, which include inflammation or irritation, and prevents complications like pneumonia and bronchitis. For example, the European Centre for Disease Prevention and Control (ECDC) reported in July 2023 that 42% of influenza specimens tested positive in the 51st week of 2022 during the 2022/2023 flu season in the EU/EEA. Positivity hovered around 28% from the 5th to the 12th week of 2023. Therefore, the increasing prevalence of influenza is fuelling the expansion of the pharyngitis treatment market.

What are the key segments defining the pharyngitis treatment market?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

Who are the key players steering the development of the pharyngitis treatment market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

What emerging trends are influencing the growth of the pharyngitis treatment market?

Leading firms in the pharyngitis treatment market are turning their focus towards creating advanced products like oral monotherapy, intending to improve patient compliance and deliver efficient, handy treatment alternatives. Oral monotherapy denotes the utilization of an individual medicine taken orally to mitigate a particular disorder or disease. This therapeutic approach implies administration of a single therapeutic agent instead of multiple combined treatments to achieve the therapy’s anticipated outcome. For example, in December 2023, The FDA granted approval to Novartis AG, a pharmaceutical corporation from Switzerland, for Fabhalta (iptacopan), marking it as the inaugural oral monotherapy for adult patients suffering from paroxysmal nocturnal hemoglobinuria (PNH). This achievement on [date] signifies a notable evolution by furnishing a novel treatment substitute that boosts hemoglobin levels, thereby abrogating the requirement for blood transfusions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12937

Which regions are most influential in expanding the pharyngitis treatment market?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: